Skip to content
OpenCapital
Get started

Integra LifeSciences IART Change in fair value of contingent consideration

Change in fair value of contingent consideration at other companies

Globus Medical logo
Globus MedicalGMED
$6.35M+3,704%
Merit Medical Systems logo
Merit Medical SystemsMMSI
-$179K-117%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's change in fair value of contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's change in fair value of contingent consideration?
Integra LifeSciences (IART) reported change in fair value of contingent consideration of -$1.29M in Q1 2026.
How has Integra LifeSciences's change in fair value of contingent consideration changed year-over-year?
Integra LifeSciences's change in fair value of contingent consideration decreased by 698.1% year-over-year, from -$162K to -$1.29M.
What is the long-term trend for Integra LifeSciences's change in fair value of contingent consideration?
Over 4 years (2021 to 2025), Integra LifeSciences's change in fair value of contingent consideration has grown at a 77.2% compound annual growth rate (CAGR), from -$2.16M to -$21.33M.
What does change in fair value of contingent consideration mean?
This represents the non-cash adjustment to the fair value of liabilities related to earn-outs or contingent payments from past business acquisitions. Changes in this value reflect updated expectations regarding the achievement of performance milestones by acquired entities. It is a critical indicator of how acquisition-related liabilities fluctuate based on operational success.